

Curriculum Vitae

Personal information Loreto Carmona

Work experience

1. Employer: Institute for Musculoskeletal Health (InMusc)
 - Start date: June 2012
 - End date: ongoing
 - Position: Scientific Director
 - Activities: Research, Education, and Health Promotion
 - Country: Spain
2. Employer: Universidad Camilo José Cela
 - Start date: Feb 2011
 - End date: Sep 2013
 - Position: College / university teaching professional
 - Activities: Teaching students and teachers (these in research methodology), research
 - Country: Spain
3. Employer: (free_lance)
 - Start date: Dec 2010
 - End date: June 2012
 - Position: Research and development department manager
 - Activities: Research Design, Consultancy, Medical writing, Education
 - Country: Spain
4. Employer: Fundación Española de Reumatología
 - Start date: Nov 2003
 - End date: Nov 2010
 - Position: Research and development department manager
 - Activities: Coordination of national and international research projects in the field of rheumatic diseases
 - Country: Spain
5. Employer: Hospital Clínico San Carlos
 - Start date: June 2002
 - End date: Nov 2003
 - Position: Medical doctor
 - Activities: Clinical practice, coordination of clinical research at the Rheumatology Department.
 - Country: Spain
6. Employer: Instituto de Salud Carlos III and Hospital de la Princesa
 - Start date: Feb 2001
 - End date: Jun 2002
 - Position: Statistical associate professional
 - Activities: Help in research to health area investigators, coordinating Cochrane initiatives in Health areas.
 - Country: Spain
7. Employer: Sociedad Española de Reumatología
 - Start date: Jun 2000
 - End date: Feb 2001
 - Position: Statistical associate professional
 - Activities: Coordination of national research projects in the field of rheumatic diseases.
 - Country: Spain
8. Employer: Spanish Medicines Agency
 - Start date: Sep 1999
 - End date: May 2000
 - Position: Medical advisor
 - Activities: Evaluate the efficacy and safety dossiers of new drugs.
 - Country: Spain

Education and training

1. Subject: Universidad Autónoma de Madrid
 - Start date: Sep 1998
 - End date: May 2002
 - Qualification: Epidemiology and Preventive Medicine Doctorate (PhD)
 - Organisation: UAM
 - Country: Spain
2. Subject: Arthritis Research Group, University of California, San Francisco
 - Start date: Jan 1996
 - End date: Dec 1997
 - Qualification: Post_doctoral fellowship
 - Organisation: UCSF
 - Country: United States
3. Subject: Hospital de la Princesa
 - Start date: Jan 1990
 - End date: Dec 1994
 - Qualification: Specialty in Rheumatology
 - Organisation: Spanish National Health System

- Country: Spain
4. Subject: Universidad Autónoma de Madrid
- Start date: Sep 1982
 - End date: Jun 1990
 - Qualification: Licenciada en Medicina y Cirugía (MD)
 - Organisation: UAM
 - Country: Spain

Additional information

Publications

<http://orcid.org/0000-0002-4401-2551>

Projects

1996 - 97	Analysis of the US National Health Interview Survey (NHIS) to e between American Whites and US Hispanics. Fellow. FIS Grant, 1
1996 - 97	Predictive factors for carpal tunnel syndrome-related disability in Valley, California. Fellow. Funded by NIH AR-20684. Individual FIS grants, BAE96/5485 and BAE97/5090.
1996 - 97	Prognostic factors and natural history of rheumatoid arthritis in a c California and followed for 18 years. Fellow. Funded by several g grants from the Spanish Society of Rheumatology and two consec
1998 - 00	EPISER: Study of the prevalence of low back pain, osteoporosis, m erythematosus and fibromyalgia in the Spanish population. Project Dohme and FIS 99/5201.
1998 - 04	EMECAR: Study of the morbidity and clinical expression of RA i Promoter: SER. Funded by Aventis. FIS support 2002, accepted. S
1998 - 04	PROAR: Study of prognostic factors of early-onset arthritis in Spa Plough, and Marató TV3.
1999 - 00	GUIPCAR: Rheumatoid arthritis clinical practice guideline. Panel
1999 - 04	COSTE-CV AR: Prospective one-year study of the associated cos Methodologist. PI: F Navarro and FJ Ballina. Promoter: SER. Fun
1999 - 10	BIOBADASER: Registry of biological therapies for the treatment Medicines Agency, Pharmacoepidemiology and Pharmacovigilanc
2001 - 02	Cochrane Review: Hormone Replacement Therapy for Preventing Gabriel. Funded by Hospital de la Princesa, Madrid.
2002	Systematic review: Utility of dual phalangeal radiographic absorp Funded by Agencia de Evaluación de Tecnologías Sanitarias FIS (
2002 - 03	Intervention for the effective resolution of work incapacity of mus 02/0893.
2003 - 04	ARTROCAD: Quality of life in knee and hip osteoarthritis". Co-m
2003 - 04	REGISPONSER: National Spondyloarthritis Registry. Co-method Rheumatology. Funded by Abbott, Schering and Wyeth.
2004 - 05	REFLECT: Rheumatological evaluation of aspects leading to exc Martín Mola. Funded by MSD.
2004 - 07	DIME: Disability of musculoskeletal origin in non-institutionalise its incidence in a health area. Methodologist. PI: Juan Ángel Jover Fundación Española de Reumatología.
2004 - 08	SERAP: Pathology management research project: Evaluation of a

	Promoter: Spanish Rheumatology Foundation. Funded by Abbott.
2005 - 06	AREXS: Salmonella reactive arthritis. Study of the July 2005 outbreak between the Spanish Society of Rheumatology, the National Epidemiology Services.
2005 - 06	COST-EA: Cost and quality of life of patients with ankylosing spondylitis. Coordination. PI Gisella Kobealt. Sponsor: Schering Plough, SA
2006	Evaluation of the efficacy of ozone therapy in rheumatic pathology. PI05/90071.
2006 - 07	Paget's disease of bone: Study of its prevalence and establishment of SER. Funded by: Novartis.
2006 - 07	GEMA: Variability in the management of gout in Spain. Methodological advisor.
2006 - 07	GUIPCAR: Rheumatoid arthritis clinical practice guideline (Update)
2006 - 07	MEXESPA: Study of the incidence of ankylosing spondylitis in Spain with juvenile-onset spondyloarthritis. PI: M ^a Luz Gamir/Loreto C
2007 - 08	3rd initiative: Recommendations for the use of methotrexate in rheumatoid arthritis. Funded by Abbott.
2007 - 08	BIOBADADADERM: Registry for the control and monitoring of dermatological diseases. Methodological advisor. Promoter: Spanish Academy of Dermatology
2007 - 08	BIOBADAMERICA: Registry for the control and monitoring of rheumatoid arthritis in Latin America. Promoter and funder: Spanish Rheumatology Foundation
2008 - 10	Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) CLI.013.
2008 - 10	ESPERANZA: Mixed management and research programme in early rheumatoid arthritis. Promoter: Spanish Rheumatology Foundation. Funded by: Wyeth.
2008 - 10	EULAR recommendations for monitoring systemic lupus erythematosus (SLE)
2008 - 13	European Musculoskeletal Conditions Surveillance and Information System (EUROMUSCIS) (UK). Funded by: EU's Second programme of community action in the field of health
2009 - 10	CARMA: Prognostic factors of cardiovascular risk in rheumatoid arthritis. Promoter: FER. Funded by Abbott
2009 - 10	emAR: Study of variability in the management of rheumatoid arthritis. Funded by Abbott.
2009 - 10	HUPI index: Development of a rheumatoid arthritis activity measure. Methodologist. PI: Isidoro González-Álvaro. Sponsor: Hospita
2010	CATALINA - On-line catalogue of Measuring Instruments in Rheumatology
2011	CONCORD: Efficacy of formal training on the Berlin index (MRI)
2011 -	Registry of uveitis in patients with Juvenile Idiopathic Arthritis. M
2011 - 12	3rd initiative: Multinational Recommendations for the Diagnosis and Management of Juvenile Idiopathic Arthritis. Heijde. Funded by Abbott.
2011 - 12	CTD-ILD Outcome Measures in Clinical Trials. Panelist. Promote

2011 - 13	Development of an online "toolbox" including indices and measures (PRO). Promoter: EULAR
2011 - 16	The BRAF and RAID study - Cross-cultural validation of two rheumatoid arthritis (RA) Fatigue and RA Impact of Disease scales. Contributor. PI: Sar...
2012 - 13	What prevents the implementation of the t2t strategy? Focus group...
2012 - 13	ACTIVATE: Adherence and persistence of biologic treatment and... Sponsor: Camilo José Cela University. Funded by Roche Farma S...
2012 - 16	UTB: Registry of Biological Therapies of the Hospital de la Princesa del Hospital de la Princesa.
2013	DLI: Recommendations for the detection, investigation, and referral of Back Pain Group. Methodologist. Sponsor: Merck Sharp & Dohm...
2013	GECOAR: Comorbidity management in rheumatoid arthritis. Methodologist. Funded by Roche.
2013 - 18	ARCO: Study on treatment compliance in patients with rheumatoid arthritis. Committee and Methodological Advisor. Sponsor: Merck Sharp & Dohm...
2014	Development of a definition for Early Osteoarthritis. Methodologist...
2014 -	Registry of systemic JIA and adult Still's disease. Methodologist...
2014 - 16	Development of a severity index for rheumatoid arthritis
2014 - 16	EULAR points to consider for monitoring (detection/prevention) of... EULAR
2014 - 16	EULAR Taskforce on the management of Familial Mediterranean Fever...
2014 - 16	EULAR Taskforce on Transition from Rheumatic Pediatric Clinic to...
2014 - 17	EJES-3D: Development of an exercise programme for spondyloarthritis involved in the exercise and management of spondyloarthritis. Promoter...
2015	White Paper on Early Arthritis in Spain. Co-methodologist. Promoter...
2015 - 16	EULAR recommendations for a core data set to support observational research. EULAR
2015 - 16	EULAR standardised procedures for rheumatology ultrasound (RI... in rheumatology) Methodologist. Promoter: EULAR
2015 - 16	GECOAP: Management of comorbidity in psoriatic arthritis. Methodologist...
2015 - 16	Models of Care for musculoskeletal health: Development of an evaluation. Curtin University.
2015 - 16	Recommendations on the management of the patient undergoing knee surgery...
2015 - 16	Reproducibility of the measurement of movement analysis by UC...
2015 - 19	Stickler syndrome registry. IP. Promoter: Spanish Stickler Syndrome...
2015 - 20	Stress coping training programme for rheumatoid arthritis. Methodologist. Hospital de la Princesa.
2015 - 22	Clinical trial to evaluate the efficacy of a mindfulness-type strategy...

SORCOM

2016	Real Remission: What is remission in arthritis? PI. Sponsor: Pfizer
2016 - 17	GECAx: Management of comorbidity in spondyloarthritis. Methodologist. Promoter: Abbvie.
2016 - 18	PRECOZ RA: SER Working Group. Qualitative study to identify technical solutions. Methodologist. Promoter Abbvie.
2016 - 18	InMind: Identifying and managing the psychosocial impact of inflammation. Merck Sharp & Dohme.
2016 - 18	RHEU-LIFE: Survey on disease perceptions and information received by patients taking biologic drugs in Spain. Scientific Committee. Promoter: MSD
2017	AR2020: Challenges of the Spanish Health System and their effects on patients. Methodologist. Promoter Abbvie.
2017 - 18	Practical aspects of biologic drug monitoring in rheumatoid arthritis. MB
2017 - 18	Viscosupplementation in non-severe knee osteoarthritis: A network of experts. Sponsor: SANOFI
2017 - 19	AFRONTAR: Dealing with the emotional and social involvement of chronic disease. Spanish Patients' Forum
2017 - 19	PROGRESAR: Prognostic factors in rheumatoid arthritis: Use in clinical practice. Exposure to evidence. Co-methodologist. Sponsor: Bristol-Myers Squibb
2017 - 19	USAS: Development and validation of an ultrasound index for disease activity. Methodologist. Promoter: Catalan Society of Rheumatology.
2017 - 20	e-SpA: Digital programme in spondyloarthritis. Coordinator. PI: EULAR
2018	GECAI: Practical materials for comorbidity monitoring in rheumatoid arthritis. Promoter: Abbvie.
2018 - 19	Dose adjustment profile in biological therapies in JIA. Methodologist. Promoter: Abbvie.
2018 - 20	Clinical Practice Guidelines in Peritoneal Dialysis. Methodologist. Promoter: Abbvie.
2018 - 20	PROGRESAR II: How should we manage poor prognostic factors in rheumatoid arthritis? rheumatologists. Methodologist. PI: J Narvaez. Sponsor: Bristol-Myers Squibb
2018 - 20	EULAR guidelines for the reporting of ultrasound studies in rheumatoid arthritis. D'Agostino. Promoter: EULAR
2018 - 21	ADHIERA: Treatment Compliance in Rheumatoid Arthritis. Co-Chair. Promoter: Abbvie.
2018 - 21	Construction of a prognostic index in lupus nephritis. Methodologist. Promoter: Abbvie.
2019	READY: Barriers and difficulties in the patient journey from diagnosis to treatment. Promoter: Abbvie.
2019 - 23	I4V-MC-JAJA and I4V-MC-JAJD: Randomized, Active-Controlled Study of the Effect of JAK Inhibitors in Rheumatoid Arthritis. Data Monitoring Committee. Sponsor: Eli Lilly
2017 - 23	OMERACT POLOS – Co-Chair. Patient relevant Outcomes in Long-term Treatment of Rheumatoid Arthritis. Promoter: Abbvie.
2019 -	Scleroderma onset cohort. Patricia Carreira, Hospital 12 de Octubre
2019 - 22	e-SpA programme: Technological endowment to reinforce research in spondyloarthritis. Promoter: Abbvie.

2019 - 20	Development of a variable defining minimal activity in psoriasis. Dermatology and Venereology.
2019 - 20	The patient journey of non-radiological axial spondyloarthritis. PI
2019 - 21	Destino Remisión: How do Spanish rheumatologists handle referral workshop. Methodologist. Promoter: Abbvie
2019 - 20	EULAR points to consider for the management of adherence in pe EULAR
2019 - 21	EULAR Recommendations for intra-articular treatments for arthro
2019 - 20	Analysis of data gaps in recommendations for the management of
2019 - 20	Classification of the severity of psoriasis. Methodologist. PI: L Sa
2019 - 20	Post-marketing registration of biological drugs in allergy - BioBal in the ARADyAL Network.
2019 - 20	Development of a tool to measure response to biological treatment Sponsor: GSK
2019 - 21	EULAR standardised operating procedures for implementing reco
2019 - 21	EULAR Recommendations for the implementation of self-manage Convenor: A Bostworth Promoter: EULAR
2020	Systematic reviews on instruments to measure disease activity and (Outcomes Measures Library). Methodologist. Sponsor: EULAR
2020	COVID-RIER: COVID-19 matched cohort study for the study of diseases. Statistics. Promoter: Inflammation and Rheumatic Disea
2020	COVID-19 EULAR: European paediatric and adult database to m RMDs. Contributor. PI: P Machado. Promoter: EULAR
2020 -	Co-THEIA (Combination THERapy with mEthotrexate and adalIm methotrexate, adalimumab, or their combination in non-infectious controlled, phase 3 open label with blinded outcome assessment s Investigación Biomédica del Hospital Clínico San Carlos. PI: Luis
2020 -	EducAR: Development of a tool for improving adherence to treatr
2020 - 23	Defining and optimising the use of qualitative research in the deve Nikiphorou
2020 -	Unmet need for patient involvement in rheumatology registries an Paul Studenic. Funded by: no funding.
2020 - 21	PENBICTA: Developing a framework for the involvement of pati
2020 - 22	ASMATAB: Prevalence and characteristics of asthma in smoking
2020 - 22	PROMETEO: Position paper on Patient-reported outcomes in HIV
2021 - 22	Systematic review on the efficacy and safety of immunotherapy an
2021 - 23	EULAR move-up implementation. PI: Fernando Esteve-López. Fu
2021 - 23	HEAD Registry: European Registry on the Impact of Allergic Dis EACCI

2021 - 22	OPENREUMA recommendations for the management of patients
2021 - 22	Part of the Advisory Board in a project for the development of SD
2021 - 22	Identification of critical items for a definition of moderate psoriatic
2021 - 23	Fibrojourney Latam: Mixed training and research project on clinical Loreto Carmona. Funded by: Viatris
2021 - 23	Gender perspective in psoriasis and psoriatic arthritis. PI: Álvaro C
2022	HAQ NEW: Critical evaluation of the HAQ questionnaire and pro Rheumatology Foundation.
2022-23	EULAR/PRES Recommendation for the Diagnosis and Management Still's Disease (AOSD). PI: Bruno Fautrel. Funded by: EULAR
2022	OPENREUMA recommendations for the management of patients Openreuma
2022 -23	Systematic review on the efficacy and safety of the use of ambulatory during or after systemic oncological therapy. Funded by: SH Med
2023-27	SQUEEZE - Maximising Impact of Disease Modifying Antirheumatic EU's Horizon 2020 research and innovation programme under gra PI: Daniel Aletaha (Vienna, Austria). Awarded: 12 million €
2023-28	SPIDeRR: Stratification of Patients using advanced Integrative m Call: HORIZON-HLTH-2022-TOOL-12-two-stage — Computational EU Grants: Application form (HE RIA and IA): V2.0 – 21.01.202 PI: Rachel Knevel (Leiden, Netherlands) Awarded: 6 138 750.00 €

Memberships

1992-	Member of the Spanish Society of Rheumatology (SER)
1995-97	Vice-President of the Spanish Sjögren's Syndrome Association.
1998-14	Fellow of the American College of Rheumatology
1998-03	Member of the editorial board of Arthritis Care and Research.
2000-2021	Member of the Standing Committee on Epidemiology of EULAR (European Leagues Against Rheumatism).
2007	Member of the Scientific Committee of the European League against Arthritis and Rheumatism 2008 at Paris
2008	Abstract Chair of the Scientific Committee of the EULAR Congress
2009	Scientific Chair of the EULAR Congress 2010 in Rome
2009-11	Member of ENcePP (European Network of Centers of Pharmacoepidemiology)
2010	Member of the Scientific Committee of the SER Congress 2011
2010	Member of the Scientific Committee of the SER Symposium on Osteoporosis 2011
2010	Member of the Scientific Committee for EULAR Congress 2011 at London
2010-11	Chair elect of the Standing Committee on Epidemiology and Health Services Research, EULAR
2010-11	EULAR representative at the European Medicines Agency (EMA). Healthcare Professional Working Group and EudraVigilance
2011-	Member of the Spanish Society of Epidemiology (SEE)
2011-14	Chair of the Standing Committee on Epidemiology and Health Services Research, EULAR
2011-12	Member of the Scientific Committee for EULAR Congress 2012 at Berlin
2012-13	Member of the Scientific Committee for EULAR Congress 2013 at Madrid
2012-	Honorary Member of the Venezuelan Society of Rheumatology
2012-16	Vice-president of the Association of Rheumatology Related Professionals (OPENREUMA)
2013-	Member of the Scientific Committee of the European Rheumatology Research Foundation
2013-14	Member of the Society for Epidemiology Research (SER)
2013-2021	Technical Secretary of the Spanish League Against Rheumatism (LIRE)
2014-	Honorary Member of the European League Against Rheumatism, EULAR

2016-	Treasurer of the Association of Rheumatology Related Professionals (OPENREUMA)
2017-18	Member of the Scientific Committee for EULAR Congress 2018 at Amsterdam
2017-2020	Member of the Public Affairs Committee for EULAR at Brussels
2017-18	Member of the Scientific Committee for Mediterranean Congress of Rheumatology 2018 at Genova
2018-19	Member of the Scientific Committee for EULAR Congress 2019 at Madrid
2019-20	Abstract Chair of the Scientific Committee of the EULAR Congress at Frankfurt (finally e-Congress)
2020-21	Scientific Chair of the EULAR Congress 2021 at Paris (finally e-Congress)
2021-2024	Member of the Scientific Advisory Board of CEDOC - Chronic Diseases Research Centre - The Research Center of NOVA Medical School- NOVA University of Lisbon
2021-22	Scientific Chair of the EULAR Congress 2022 at Copenhagen
2021-25	Chair of Advocacy of EULAR, the European Alliance of Rheumatology Associations
1998-03	Member of the editorial board of Arthritis Care and Research
2001-03	Member of the Editorial Board of Evidence Based Medicine Spanish Edition
2002-04	Member of the editorial board of the Revista Española de Reumatología.
2004-	Member of the Editorial Board of Current Rheumatology Reviews
2005-11	Associate Editor, Arthritis Care and Research
2008-	Member of the Editorial Board of Annals of the Rheumatic Diseases
2008-	Member of the Editorial Board of Rheumatologie Clinique
2010-	Member of the Editorial Board of Clinical Experimental Rheumatology
2011-12	Member of the Editorial Board of Acta Reumatológica Portuguesa
2012-17	Editor-in-Chief Rheumatology International, Nov. 2012-Oct. 2017

Panels of evaluators

1997	Collaboration as an expert in rheumatological issues with the Sub directorate General of Medicines of the Ministry of Health, Spain. Evaluation of Concept Papers on the treatment of osteoarthritis and arthritis. 31 October and 26 November 1997
2000 -	Member of the panel of evaluators of the Sub Directorate General of Health Research (ANEP, FIS).
2000 -	Member of the panel of assessors of the Spanish Society of Rheumatology.
2009	Evaluator in the call for Research in Biomedicine and Health Sciences in the Centres of the Galician Public Health System.
2009	Evaluator in the EULAR Grant Advisory Council (Scleroderma Grant Advisory Council 2009).
2011	Participant in the evaluation of projects with conflict of interest of the FIS 2011 call for proposals.
2011	Evaluation of the University of Cordoba's master's degree
2012	Evaluator for Professorship for epidemiologic Research of the German Rheuma Foundation
2013- 19	Member of the Scientific Committee of FOREUM Foundation for Research in Rheumatology
2016	External referee in the scientific evaluation of proposals submitted to the European Research Council (ERC) Starting, Consolidator and Advanced Grant Calls 2016
2017	Forskerprosjekts evaluator for the BEHANDLING programme of the Norwegian Research Council.
2019	Coordinator of the evaluation of research and development units in the "Public Health, Nursing, Sport and Health Technologies, Rehabilitation and Welfare" Programme for the Fundação para a Ciência e a Tecnologia (FCT), Portugal.
2019	Forskerprosjekts evaluator for the BEHANDLING programme of the Norwegian Research Council.
2021	FWF Austrian Science Fund
2021	Evaluator for The Research Council of Norway Centre for Clinical Treatment Research 2021
2021	Evaluator for the Sub directorate General for Evaluation and Promotion of Research (SGEFI).
2022	Project evaluator in the Programme "Call for R&D Projects in All Scientific Domains - 2022", area "Health and Sport Sciences" for the Fundação para a Ciência e a Tecnologia (FCT), Portugal.
